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Summary: An inhibitor of neutral proteinases 
was isolated from the cytosol of bovine leuko-
cytes by anion exchange chromatography on 
Mono Q and gel filtration on a HPLC TSK 
column. The gel filtration resulted in two frac-
tions with inhibitory activity which could be 
identified by sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) 
under nonreducing conditions as dimer and 
monomer of the inhibitor. The latter was 
shown to be homogeneous in SDS-PAGE with 
an apparent molecular mass of 40 kDa, with 
calibrated HPLC a molecular mass of 36.5 kDa 
has been determined. Isoelectric focusing fol-
lowed by Western blot analysis revealed four 
bands in the pH range of 5.0 to 5.9. The inhibi-
tor was found in bovine polymorphonuclear 
neutrophils (PMN), whereas lymphocytes and 
monocytes lacked this protein. No immunologi-
cal cross-reactivity between the described cell-
derived PMN-inhibitor (PMN-I) and oc{ -protein-
ase inhibitor was detectable. The mechanism 
of inhibition for the serine proteinases chymo-
trypsin, trypsin, pancreatic elastase and leuko-
cyte elastase was studied. PMN-I could not bind 
to PMS-chymotrypsin. The reaction of the 
serine proteinases with the PMN-I was charac-
terized by the determination of the association 
rate constant kon. 
Inhibitoren neutraler Proteinasen aus PMN-Leukozyten. 
L Reinigung und Charakterisierung eines Inhibitors neutraler Proteinasen aus 
polymorphkernigen Neutrophilen des Rindes 
Zusammenfassung: Aus dem Cytoplasma von 
Rinder-Leukozyten wurde ein Inhibitor neutra-
ler Proteinasen mit Hilfe einer Kombination von 
Anionenaustausch-Chromatographie an einer 
Mono-Q-Säule und Gelfiltration an einer HPLC-
TSK-Säule gereinigt. Die Gelfiltration resultierte 
in zwei Fraktionen mit inhibitorischer Aktivität, 
die in der SDS-Polyacrylamid-Gelelektrophorese 
(SDS-PAGE) unter nichtreduzierenden Bedin-
gungen als die dimere und die monomere Form 
des Inhibitors identifiziert werden konnten. 
Letztere erwies sich in der SDS-PAGE als homo-
gen mit einer Molekularmasse von 40 kDa. Da-
gegen führte die Bestimmung der Molekular-
masse an einer kalibrierten HPLC-Säule zu einer 
etwas geringeren Molekularmasse von 36.5 kDa. 
Bei der isoelektrischen Fokussierung mit an-
schließendem Western-Blot traten vier Banden 
Enzymes: 
Bovine chymotrypsin (EC 3.4.21.1), human leukocyte elastase (EC 3.4.21.37, formerly EC 3.4.21.11), porcine 
pancreatic elastase (EC 3.4.21.36, formerly EC 3.4.21.11), porcine pancreatic trypsin (EC 3.4.21.4). 
Abbreviations: 
ACD, acid citrate dextrose; AMC, 7-amino-4-methylcoumarin; DMSO, dimethylsulfoxide; FPLC, fast-protein liquid 
chromatography; Hepes, 4-(2-hydroxyethyl)-l-piperazinethanesulfonic acid; HPLC, high-pressure liquid chromatog-
raphy; IEF, isoelectric focusing; MeOSuc, 4-methoxycarbonylpropionyl; Nan, 4-nitroanilide; P O | e / N a C l , phosphate-
buffered saline; PMN, polymorphonuclear neutrophils; PMN-I, PMN-inhibitor; PMSF, phenylmethylsulfonyl f luorid; 
SBzl, thiobenzylester; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 
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im pH-Bereich von 5.0 bis 5.9 auf. Weiterhin 
konnte gezeigt werden, daß der Inhibitor ein 
zellspezifisches Protein der polymorphkernigen 
Neutrophilen (PMN) ist; Lymphozyten und 
Monozyten besitzen dieses Protein nicht. Der 
PMN-inhibitor und ax -Proteinase Inhibitor ha-
ben keine gemeinsame immunologische Spezifi-
tät. Der Hemmungsmechanismus wurde für die 
Serin-Proteinasen Chymotrypsin, Trypsin, 
Pankreas-Elastase und Leukozyten-Elastase 
untersucht. Der PMN-I reagierte nicht mit PMS-
Chymotrypsin. Die Reaktion der Serin-Pro-
teinasen mit PMN-I wurde durch die Bestim-
mung der Geschwindigkeitskonstanten der 
Assoziation kon charakterisiert. 
Key words: Leukocyte elastase inhibitor, granulocytes, serine proteinases, cytosolic inhibitor. 
Acute inflammatory processes are characterized 
by an accumulation of PMN 1 1 1 , which release a 
series of enzymes by extrusion of their granules 
during phagocytosis or cell disintegration121. 
Besides acid hydrolases, mainly neutral serine 
proteinases such as leukocyte elastase and 
cathepsin G as well as the metallo proteinase 
collagenase[31 are released. Furthermore, toxic 
oxygen radicals are produced in connection 
with the respiratory burst of the cells141. The 
extracellularly released enzyme activity in the 
serum is controlled by plasma proteinase in-
hibitors like a r P I i s l and a2-macroglobulin l61. 
In addition, inhibitors of neutral proteinases 
were found in the cytosol of leukocytes and 
macrophages in man 1 7 " 9 1 , pig 1 1 0 1 , rabbit 1 1 1 1, 
horse1 1 2 3 and cattle 1 1 3 , 1 4 1 . 
The relevance of inhibitors, found in the cytosol 
of leukocytes, is still under discussion. Protec-
tion of cytoplasmic proteins against proteinases 
released from the granules during phagocytosis 
seems to be a major function 1 9' 1 2 , 1 5 1. Cytosol 
inhibitors may also be responsible for the 
blocking of enzymes when cell degradation 
takes place during inflammation1121, while the 
concentration of plasma inhibitors is possibly 
not efficient in tissue for the control of pro-
teinase activity111. 
This report describes the purification and bio-
chemical characterization of a cytosolic neutral 
serine proteinase inhibitor from bovine PMN. 
Materials and Methods 
Chemicals 
The enzyme substrates Suc[Ala] 2 ValNan, SucfAla^Nan, 
Suc[Ala] 2ProPheNan, Suc[Ala] 2ProPheSBzl and 
ZLysSBzl were purchased from Bachem AG, Buben-
dorf, Switzerland, NBenzoylArgNanHCl was obtained 
from Sigma, St. Louis, MO, U.S.A., and Ellmanns rea-
gent (5,5'-dithiobis-2-nitrobenzoic acid) was a product 
of Serva, D-6900 Heidelberg. Bovine chymotrypsin was 
from DeNovo, Bagsvaerd, Denmark. Porcine trypsin and 
porcine pancreatic elastase were from Sigma, and human 
leukocyte elastase was a generous gift of Dr. S. Neumann 
(Merck, D-6100 Darmstadt). Human ax-?\ was obtained 
from Sigma. Bovine α^-PI was a product of Boehringer, 
D-6800 Mannheim. Trasylol (Aprot inin) was purchased 
from Bayer, D-5090 Leverkusen. Marker proteins for the 
calibration of the HPLC column and the SDS-PAGE 
were purchased from Sigma. Chemicals for SDS-PAGE 
were obtained from Bio-Rad, Richmond, CA, U.S.A. 
Chemicals and materials for IEF were purchased from 
LKB, Bromma, Sweden. Percoll was a product of Phar­
macia, D-7800 Freiburg. A l l other chemicals of highest 
purity available were from Roth (D-7500 Karlsruhe) 
and Merck. 
Protein determination 
Protein was determined with the Ninhydrin reagent^ 1 6 1 
using bovine serum albumin as standard. 
Gel electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electro­
phoresis (SDS-PAGE) in 10% gels was carried out by 
the method of Laemml i t 1 7 3 under nonreducing condi­
tions. The samples were applied in 0 .5^g to 2.0-Mg 
aliquots in a volume of 20 μι, respectively. Proteins 
were stained wi th Coomassie Brillant Blue R 250 
(Serva, D-6900 Heidelberg). 
Isoelectric focusing ( IEF) was performed wi th 5% 
Polyacrylamide gels containing 2.4% carrier ampholytes 
in the pH range of 3.5 to 9.5 according to Görg et a l . l 1 8 ! . 
Protein samples were applied in 20-ßg to 60-ßg aliquots 
in a volume of 20 μ/, respectively. Coomassie Brillant 
Blue R250 was used for protein staining. Prior to stain­
ing the pH-gradient was determined wi th a pH surface 
electrode. 
Western blot in connection with staining by 
1251-labeled leukocyte elastase 
Iodination of human leukocyte elastase was performed 
according to Greenwood and Hunter^ 1 9 ! . Subsequent 
to the radiolabeling of the enzyme non-radioactive 
iodide was added to the mixture to give a total concen­
tration of 0.35% (w/v) . Unbound iodine was separated 
from 1 2 5I-elastase by the use of a Sephadex G-25 col­
umn which was run wi th 0.1 mol/ / Tris, 0.5 mol / / 
NaCl, 1 % ovalbumin (w/v) , adjusted to pH 7.5 wi th 
HCl. 
The procedure used for Western blot has been described 
by Towbin et a l J 2 ° l . After blotting the electrophoreti-
cally separated proteins the nitrocellulose filters were 
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incubated in phosphate-buffered saline ( P O | e / N a C l ; 
140 mmol/ / NaCl, 3 mmol / / KCl , 8 mmol/ / N a 2 H P 0 4 χ 
2 H 2 0 , 1.5 m m o l / / K H 2 P 0 4 , p H 7.2) containing addi­
tionally 0.05% Tween 20 and 2 mol / / NaCl to prevent 
unspecific binding of the 1 2 S l - l abe led leukocyte ela-
stase^21!. Subsequently the nitrocellulose filters were 
incubated wi th 3 μ€ι 1 2 5 I - labe led enzyme in 10 m/ 
buffer for 3 h at room temperature wi th constant 
rocking. Finally the filters were washed twice wi th 
buffer, air-dried and exposed to a Kodak X-Omat 
AR film for 1 - 3 days at - 80 °C. 
Preparation of bovine leukocytes 
Blood of normal cattle was collected at the slaughter 
house in bottles containing one fifth of the final volume 
of the stabilizer ACD (acid citrate dextrose: 45 mmol / / 
sodium citrate, 21 mmol / / citric acid, 74 mmol / / glu­
cose monohydrate). After washing the cells wi th Ρ Ο ^ θ / 
NaCl (15 min/1 000 χ g) erythrocytes were lysed by the 
addition of 0.017 mol / / Tris, 0.14 mol / / ammonium 
chloride, pH 7.2. The remaining leukocytes were washed 
wi th PO^ e /NaCl and adjusted to the required concen­
tration. 
Separation of bovine leukocytes 
Bovine leukocytes (1.6 χ 10 8 cells/m/) were separated 
using a discontinuous gradient of Percoll according to 
Hjorth et a l J 2 2 J . The interphase, containing lympho­
cytes as well as monocytes, and the phase between the 
two Percoll solutions, containing PMN, were removed 
and washed twice wi th PO^ e /NaCl. Both cell fractions 
were adjusted to an amount of 5 χ 10 7 cells/m/. Dif­
ferent cell types were identified using Giemsas and 
May-Grünwald's staining solutions according to Pappen-
h e W 2 3 J . 
Purification of the PMN-I 
Leukocytes (1 χ 10 8 cells/m/) transfered to P O ^ / N a C l 
containing 8% saccharose were homogenized by nitrogen 
cavitation (20 atü, 13.5 m i n ) l 2 4 l . The cytosol was sepa-
rated from the membranous particles by ultracentri-
fugation for 60 min at 220000 xg. Subsequently, pro-
tein was precipitated by the addition of 2 mol / / am-
monium sulfate to the supernatant, i.e. the cytosol. 
After 1 h of stirring at 2 °C the precipitate was separated 
by centrifugation at 4000 χ g for 45 min. The super­
natant containing the inhibitor activity was dialysed 
against 50 mmol / / Tris/phosphate, pH 7.5, and con­
centrated by ultrafi l trat ion wi th negative pressure 
using a Visking dialysis tube to a concentration of 40 mg 
to 45 mg protein/m/. Two ml of the sample was applied 
to a prepacked FPLC-anion exchange chromatography 
column (Mono Q HR 10/10, Pharmacia). The elution 
was performed at 20 C by a linear concentration gra­
dient ranging from 0.02 mol / / to 0.56 mol / / Tris/phos­
phate, pH 7.5, w i t h a flow rate of 0.5 m//min using a 
chromatography unit of L K B . Five-m/ fractions were 
collected at 4 °C and aliquots of each fraction were 
tested for inhibi tory activity against leukocyte elastase. 
Fractions wi th inhibi tory activity were pooled, concen­
trated by ultrafi l t rat ion and dialysed against 0.1 mol / / 
phosphate, 0.1 mol / / NaCl, p H 6.8. The dialysed ma­
terial (10—30 mg protein) was applied in 2 ml to a 
calibrated preparative HPLC-gel permeation chromatog­
raphy column (Ul t ro Pac TSK G 2000, LKB) for 
further purification. The calibration of the column was 
obtained wi th marker proteins as indicated (Fig. 2) ac­
cording to Laurent and Ki l l ander l 2 5 ! . Protein was eluted 
wi th 0.1 mol//phosphate, 0.1 mol / /NaCl , pH 6.8, and 
the flow rate was 0.5 m//min. Five-m/ fractions were 
collected, analysed by SDS-PAGE (not shown) and 
tested for inhibi tory activity against leukocyte elastase. 
Reduction of the PMN-I fractions with mercaptoethanol 
The PMN-I samples (each 0.6 mg protein in 3.8 ml 
0.5 mol / / Tr is /HCl pH 8.1) were reduced by the addition 
of mercaptoethanol to a final concentration of 0.1 mol/ / . 
After incubation of the reaction mixtures for 60 min 
at 20 C iodoacetamide was added to a final concen­
tration of 0.1 mol / / and the mixtures were incubated 
further 60 min at 2 °C. The samples were dialysed over­
night against PO | e /NaCl and analysed for their inhibi­
tory activity against leukocyte elastase and by SDS-
PAGE. 
Activity and inhibition measurements 
The enzyme assays were performed in a final volume of 
1 ml and at a temperature of 25 °C. The velocity of reac­
tion of the enzymes with the substrates ( A / i ^ s / m i n ) 
was determined using the Eppendorf calculator (CKΕ 
6455) for the first 2 min subsequent to the addition of 
substrate. For the determinations o f the type of inhibi­
t ion , the serine proteinases were first incubated wi th 
PMN-I for 5 min at 25 °C before adding the appropriate 
substrate. Inhibi t ion was studied using the methods of 
Lineweaver and B u r k l 2 6 ! and Henderson^ 2 7!. The as­
sociation rate constant k o n was measured and calculated 
according to B i e t h l 2 8 ! . 
Human leukocyte elastase was assayed according to 
Wenzel et a l . l 2 9 ! using a buffer system of 0.1 mol / / 
Hepes, 2 mol / / NaCl and 0.05% Tri ton X-100 (v/v) 
adjusted to p H 8.0 w i th ammonia. The photometrical 
determination o f the type of inhibi t ion was accomplished 
wi th 3.9 nmol / / enzyme and PMN-I in a range of 
1.0 nmol/ / to 3.15 nmol/ / . Suc[Ala] 2 ValNan dissolved 
in dimethylsulfoxide (DMSO) was used as substrate in 
a range of 0.2 mmol to 2 mmol (DMSO < 10% of the 
assay volume). The association rate constant k o n was 
fluorimetrically measured wi th 0.5 mmol/ / MeOSuc-
[Ala ] 2 ProVa lAMC as substratel 3 0!, 0.5 nmol/ / leuko­
cyte elastase and 0.5 nmol / / PMN-I using the same assay 
buffer as described. For the calculation of the specific 
inhibitory activity of PMN-I ( IU/mg protein) according 
to Bergmeyer^ 3 1! an extinction coefficient of e = 1.3 / 
m m o l - 1 m m - 1 was determined. 
For the photometrical determination of the type of in­
hibi t ion 7.8 nmol / / porcine pancreatic elastase was 
tested in 0.2 mol / / Tris, adjusted to pH 8.0 wi th HCl 
wi th the substrate Suc[Ala] 3 Nan (first dissolved in 
DMSO) in the range of 0.2 mmol / / to 0.8 mmol/ / and 
PMN-I in the range of 5.3 nmol/ / to 13.1 nmol// . k o n 
was fluorimetrically determined w i t h 0.5 mmol/ / 
M e O S u c [ A l a ] 2 P r o V a l A M d 3 ° l , 5 nmol / / pancreatic 
elastase and 5 nmol / / PMN-I in 0.2 mol / / Tris/HCl, 
pH 8.0. 
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Bovine chymotrypsin was assayed according to Del Mar 
et a l . l 3 2 ! wi th 50 mmol / / Tris, 0.4 mo l / / NaCl and 0.05% 
Tr i ton X-100 (v/v) adjusted to pH 7.8 w i th HCl as buffer. 
1.2 nmol/ / enzyme and PMN-I in the range of 0.6 nmol/ / 
to 2.0 nmol/ / were used for the determination of the 
type of inhibi t ion. The association rate constant k o n was 
photometrically measured w i t h 1 nmol / / enzyme, 
1 n m o l / / P M N - I , 0.1 mmol / / Suc[Ala] 2ProPheSBzl and 
0.24 mmol/ / Ellmanns reagent [5,5'-dithiobis-(2-nitro-
benzoic a c i d ) ] l 3 3 l . The latter two substances were first 
dissolved in DMSO. The final concentration of DMSO 
in the assay was 4%. 
Porcine trypsin was dissolved in 2.5 m m o l / / HCl to a 
concentration of 0.7 Mmol/ / and was further diluted wi th 
buffer (0.2 mo l / / Tris, 0.05% Tr i ton X-100 adjusted to 
pH 8.0 wi th HCl) . The concentration of enzyme for the 
determinations o f the type of inh ib i t ion was 14.2 mmol / / 
per assay, using NBenzoylArgNan · HCl (dissolved in 
bidistilled water) as substrate in a range of 0.2 mmol / / 
to 1.7 mmol/ / . PMN-I was added in the range of 
4.2 nmol / / to 8.4 nmol/ / . For the photometrical deter­
mination of k o n 0.5 n m o l / / t rypsin, 0.5 nmol / / PMN-I 
and the substrate combination of 0.5 mmol / / ZLysSBzl 
and 0.24 mmol / / Ellmanns reagent were used^ 3 4! (4% 
DMSO per assay), in the above-mentioned assay buffer. 
The enzymes as well as the PMN-I sample used in the 
assays were previously active site t i t rated, i.e. the per­
centages of active molecules were determined using 
corresponding substrates and inhibitors respectively. 
First of all trypsin was ti trated w i t h the covalently 
binding substrate 4-nitrophenyl guanidinobenzoate 
by the method of Shaw et al. as described in r e f J 3 5 ! . 
The inhibitor aprotinin, required for the standardiza­
t ion of chymotrypsin, was assayed by the reaction 
w i t h titrated trypsin and found to be 100% active. 
Both the inhibi tor and the enzyme were standardized 
by the above-mentioned photometrical enzyme assays. 
Subsequently, chymotrypsin was taken for the t i t rat ion 
of human -PI. This inhibi tor was used for the titra­
t ion of leukocyte as well as pancreatic elastase using the 
corresponding photometrical enzyme assays. PMN-I was 
active site t i trated by the already titrated serine pro­
teinases using again the corresponding photometrical 
enzyme assays. The percentage o f active molecules was 
calculated from the complex-forming enzyme- and in­
hibitor-molecules, respectively, in relation to the total 
concentration of the corresponding molecules in the 
assay. 
Immunological analysis in agarose gels 
For the preparation of antisera rabbits were immunized 
with c^-PI and PMN-I according to Mossmann et a l J 3 8 J 
wi th an amount of 750 μ% antigen per animal. In the 
latter case PMN-I was first bound to chymotrypsin, 
which was immobilized on Eupergit Ö 3 1 \ assuming that 
the complex would be of higher antigenicity than the 
isolated inhibitor. Both antisera were tested for their 
reaction wi th o^-PI and PMN-I according to Ouchter-
lony* 3 9 ! . 
Results and Discussion 
Comparison of the inhibitory activity of PMN 
and lymphocytes-monocytes 
The leukocytes, separated by discontinuous 
Percoll gradients, were homogenized and tested 
for their inhibitory activity in the leukocyte 
elastase assay. In contrast to the PMN-fraction 
only a low specific inhibitory activity was found 
in the lymphocyte-monocyte fraction. The latter 
fraction was contaminated by 13% PMN. There-
fore, it could be calculated that the inhibitory 
activity of the lymphocyte-monocyte fraction 
was due to the residual PMN (Table 1). This 
result gives evidence for the bovine inhibitor 
of neutral proteinases being a PMN-specific 
protein. 
Table 1. Comparison of the specific inhibitory activity of PMN 
and lymphocytes-monocytes. 
Sample Content Content of Specific 
of PMN lymphocytes inhibitory 
and activity3 
monocytes 
[%] [%] [IU/mg protein] 
PMN cell 98 2 0.042 
fraction 
Lymphocyte-
80 b monocyte 13 0.0053 
cell fraction 
Inhibition of leukocyte elastase. 
The remaining 7% were undifferentiated cells. 
Preparation of PMS-chymotrypsin 
PMS-chymotrypsin was prepared according to the 
method of Ako et a l J 3 6 l . In detail, 500 mg chymo-
trypsin in 50 ml 0.1 mol / / Tris buffer, p H 8.0, con-
taining 0.1 mol / / NaCl, 0.12 mol / / CaCl 2 and 13% 
methanol were ti trated w i t h 0.04 mo l / / PMSF (dissolved 
in acetone) by adding 0.1-m/ aliquots at five-minute 
intervals unt i l no enzymatic activity could be deter-
mined in the photometrical assay. The PMS-chymo-
trypsin preparation was dialysed overnight against 
1 mo l / / potassium phosphate p H 7.0 and in order to 
test the binding o f PMN-I to PMS-chymotrypsin, the 
latter was first immobilized on Eupergit Ö31h 
Purification of PMN-I 
The following purification procedure was 
established: 
(i) ammonium sulphate precipitation, 
(ii) anion exchange chromatography (Fig. 1) 
and, 
(iii) gel permeation chromatography (Fig. 2). 
The result of a typical purification procedure 
is summarized in Table 2 showing a 60-fold 
concentration of the PMN-I and a yield of 
2.3%. In gel permeation chromatography two 
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Fig. 1. Anion exchange chromatog-
raphy subsequent to ammonium 
sulphate precipitation on a FPLC 
Mono Q HR 10/10 column (Phar-
macia). 
Trisphosphate was used as buffer 
in a concentration range from 
0.02 mol / / to 0.56 mol / / ( —— - , 
right ordinate). Protein concentra-
t ion is given as absorption at 280 
nm ( , left ordinate). The 
PMN-I enriched fraction is marked 
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Elution volume (m/J 
Table 2. Purification of the bovine PMN-inhibitor from leukocytes. 
The data represent one preparation as an example of the purification procedure. 
Step Total protein Total inhibitory Specific inhibitory Purification Purification 
activity3 activity 3 factor yield 
Imgl i i u i [IU/mg proteinj [%1 
1. Leukocyte homogenate 1390 44.0 0.0317 1 100 
2. Leukocyte cytosol 580 44.7 0.077 2.4 101.6 
3. Ammonium sulphate precipitation 104 33.8 0.325 10.2 76.8 
4. Anion exchange chromatography 3.13 4.4 1.4 44.2 10.0 
5. Gelpermeation chromatography 
Fraction a: 0.32 0.16 0.5 _ -Fraction b: 0.56 1.0 1.9 60.0 2.3 
Inhibition of leukocyte elastase. 
Table 3. Effect of the reduction by mercaptoethanol on the 
specific inhibitory activity of the PMN-I fractions a and b. 
100 160 120 140 
Elution volume [m/] 
Fig. 2. Gel permeation chromatography o f the PMN-I 
enriched fraction from FPLC on a calibrated HPLC 
Ultro Pac TSK G 2000 column (LKB) . 
0.1 mol / / phosphate, 0.1 mol / / NaCl, pH 6.8, was used 
as buffer. Protein concentration is given as absorption 
at 280 nm. The inhibi tory active fractions are indicated 
by a and b. 
180 
Sample Specific inhibitory activity 
[IU/mg protein J a 
prior to subsequent to 
reduction reduction 
PMN-I, fraction a 0.5 1.3 
PMN-I, fraction b 1.95 2.1 
Protein concentration was determined by Ninhydrin reaction. 
peaks - (a) and (b) — with a molecular mass 
of 73 kDa and 36.5 kDa, respectively, were 
obtained which differed in their specific in-
hibitory activity (Table 3). Whereas PMN-I frac-
tion (a) appears to contain a minor contamina-
tion, the single band obtained with fraction 
(b) indicate the purity of this preparation 
(Fig. 3). 
The PMN-I fractions were stored frozen at 
- 80 °C. At this temperature the PMN-I is stable 
for 5 to 6 months. 
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a b e d 
Fig. 3. SDS-PAGE of the PMN-I monomer and dimer 
under nonreducing conditions in 10% acrylamide. 
The samples were preincubated wi th sample buffer for 
5 min at 100 °C. a) PMN-I, fraction a; b) PMN-I, fraction 
b; c) PMN-I fraction a, preincubated wi th mercapto­





a b e d 
Chemical and physical characteristics 
The molecular mass of the monomeric PMN-I 
could be determined as 36.5 kDa using a cali­
brated HPLC column (Fig. 2) and 40 kDa under 
nonreducing conditions in the SDS-PAGE 
(not shown). 
The granulocyte-derived inhibitor mentioned 
by Marossy et a l . ' 1 3 , 4 0 1 has a molecular mass of 
50 kDa and is therefore not identical with the 
PMN-I described in the paper. 
On I E F , PMN-I fraction (b) showed five protein 
bands with isoelectric points of 5.0, 5.5, 5.7, 5.9 
and 6.3, whereas fraction (a) displayed only the 
band of pi 5.0 (Fig. 4, A). The bands of pi 5.0, 
5.5, 5.7 and 5.9 formed complexes with 1 2 51-
labeled leukocyte elastase (Fig. 4, B), whereas 
the band of pi 6.3 did not bind the radiolabeled 
enzyme. 
As shown in Table 3, treatment of PMN-I frac­
tion (a) with mercaptoethanol followed by alky-
lation increased the specific inhibitory activity 
(IU/mg protein) from 25% to 62% of that of 
fraction (b). The activity of the latter was only 
marginally increased. When, however, the sam-
B 
b d 
Fig. 4. IEF of the PMN-I wi th subsequent Western blot in 5% acrylamide wi th a pH range of 3.5 to 9.5. 
A ) Protein staining wi th Coomassie Brillant Blue R250. B) Western blot using 1 2 S I - l abe led leukocyte elastase. 
a) PMN-I, fraction a; b) PMN-I, fraction b; c) Bovine a r P I ; d) Human α Γ Ρ Ι . 
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1/(5] V[S) 
Fig. 5. Lineweaver-Burk plots of the inhibi t ion of serine proteinases by PMN-I. 
Reciprocal plots of the velocity υ of the enzyme reaction versus the concentration of the substrate S [mmol / / ] in the 
presence of different fixed concentrations o f PMN-I. A ) 1.2 nmol/ / chymotrypsin, incubated wi th 1.97 nmol/ / PMN-I 
( A ) , 1.3 nmol / / PMN-I (Δ) , 0.66 nmol/ / PMN-I ( · ) , respectively, without PMN-I ( ο ) . B) 14.2 nmol/ / trypsin, incubated 
wi th 8.4 nmol / / PMN-I 6.3 nmol/ / PMN-I (Δ) , 4.2 nmol// PMN-I ( · ) , respectively, without PMN-I (o). C) 3.9 nmol / / 
leukocyte elastase, incubated wi th 3.15 nmol/ / PMN-I (A), 2.1 nmol/ / PMN-I (Δ) , 1.0 nmol/ / PMN-I ( · ) , respectively, 
without PMN-I (o). D) 7.8 nmol/ / pancreatic elastase, incubated wi th 13.1 nmol / / PMN-I (A), 9.2 nmol/ / PMN-I (Δ) , 
5.3 nmol / / PMN-I ( · ) , respectively, without PMN-I (o). 
pies were applied to SDS-PAGE the reduced 
fraction (a) migrated at the same rate as fraction 
(b) which in turn did not differ from the non-
reduced fractions (Fig. 3). 
The behaviour of PMN-I fraction (a) on reduc­
tion by mercaptoethanol and its molecular mass 
suggest that this material is a dimer of PMN-I 
contained in fraction (b). In the following 
studies, only the properties of PMN-I monomer 
(fraction b) were further investigated and the 
name PMN-I was used for this preparation. 
Inhibitory properties 
A prerequisite for the calculation of the kinetic 
data is the determination of the proportion of 
active molecules of the enzyme or the inhibitor 
solutions. Therefore, active-site titrations were 
performed. The percentages of catalytically 
active enzyme molecules were in a range of 
40% to 70% for the tested serine proteinases, 
whereas in the two inhibitor solutions — c^-PI 
and PMN-I — 10% of the molecules were active. 
The reciprocal plotting of the kinetic data ap­
parently demonstrate that the interaction of 
PMN-I with serine proteinases is a non-com­
petitive one (Fig. 5). But, if the inhibitor is 
tightly bound to the enzyme a competitive 
inhibition mechanisms is virtually indistinguish­
able from a non-competitive mechanism under 
these circumstances as shown by Henderson1271. 
Thus a clear definition on the inhibition mecha­
nism cannot be given. However, the fact that 
PMN-I does not bind to PMS-chymotrypsin 
may indicate that the reactive OH-group of the 
1340 Neutral Proteinase Inhibitor in Bovine PMN-Leukocytes Vol. 368 (1987) 
serine residue in the active site of the enzyme is 
involved in the reaction mechanism of inhibitor 
and serine proteinase (Table 4) as postulated by 
Valentine et a l . 1 1 4 1 . 
Table 4. Binding assay of PMN-I to chymotrypsin and PMS-
chymotrypsin, both coupled to Eupergit C. 
PMN-I 
sample 
Specific inhibitory activity 









a The specific inhibitory activity was tested with human 
leukocyte elastase. 
b The measurement is below the linear correlation. 
Additionally, it should be mentioned that the 
PMN-I binds very tightly to immobilized chymo­
trypsin and only treatment with high urea con­
centration (6 mol//) could dissociate the en­
zyme-inhibitor complexes resulting in inactive 
inhibitor molecules (data not shown). Therefore, 
according to the definition given by Bieth l 2 8 J 
the association of chymotrypsin and PMN-I 
should be characterized to irreversible. 
This is comparable to the inhibitory properties 
of a r P I , the most important inhibitor of serine 
proteinases in plasma'5 J . a!-PI reacts with pro­
teinases in a noncompetitive or irreversible way 
resulting in a hydrolytic cleavage of the inhibitor 
molecule and a strong complex forming of the 
main part of the inhibitor with the enzyme l 4 1 ]. 
The most significant constant for the classifica­
tion of inhibitors is the association rate constant 
2 4 7 2 4 6 8 10 
r [min l f [minl 
Fig. 6. Determination of the association rate constants k o n of the inhibit ion of serine proteinases by PMN-I. 
The activity of the enzyme subsequent to complex forming wi th PMN-I ( in percent) versus the incubation time [min] 
of the complex before starting the assay. Inserts: Reciprocal plots of the concentration of resting free enzyme sub­
sequent to complex forming versus incubation time. A ) 1 nmol// chymotrypsin, incubated wi th 1 nmol/ / PMN-I and 
the substrate combination of 0.1 m m o l / / Suc(Ala) 2ProPheSBzl and 0.24 mmol / / Ellmanns reagent. Β) 0.5 nmol/ / 
trypsin, incubated wi th 0.5 nmol / / PMN-I and the substrate combination of 0.5 mmol / / ZLysSBzl and 0.24 mmol / / 
Ellmanns reagent. C) 0.5 nmol / / leukocyte elastase, incubated wi th 0.5 nmol/ / PMN-I and 0.5 mmol / / MeOSuc(Ala) 2 -
ProValAMC. D) 5 nmol / / pancreatic elastase, incubated wi th 5 nmol// PMN-I and 0.5 mmol/ / MeOSuc(Ala) 2ProVal-
AMC. 
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Table 5. Association rate constants of the inhibition of serine proteinases by PMN-I. 
Enzyme Origin of the enzyme Substrate k o n (//(mol χ s)Ja 
Chymotrypsin Bovine pancreas Suc(Ala)2ProPheSBzl 8.7 χ 10 6 
Elastase Human PMN MeOSuc(Ala)2ProValAMC 3.8 χ 10 7 
Elastase Porcine pancreas MeOSuc(Ala)2ProValAMC 1.3 χ 10 6 
Trypsin Porcine pancreas ZLysSBzl 1.0 χ 10 7 
The calculations of k o n were based on a molecular mass of 38 kDa for PMN-I. 
^on · For PMN-I relative high values were cal­
culated (Fig. 6, Table 5) which indicates that 
PMN-I reacts very fast with serine proteinases. 
Other physiologically active inhibitors like 
a r P I show comparable values for A : o n [ 4 2 ' 4 3 J . 
Immunological properlies 
In the immunodiffusion assay according to 
Ouchterlony, the rabbit antiserum raised to 
of!-PI showed no cross reaction with PMN-I 
and vice versa (Fig. 7). This immunological 
discrepancy indicates the different origin of 
both inhibitors. 
The physiological relevance of PMN-I may be 
restricted to the protection of the cell from 
Fig. 7. Immunological specificity of α^-PI and PMN-I 
in agarose gels. 
A ) a r P I ; B) PMN-I. 1-5) A n t i - a r P I antiserum in the 
concentration range from concentrated (No. 1) to 1:16 
diluted (No. 5) antiserum. 6 - 8 ) Normal serum of rabbit 
in the concentration range from concentrated (No. 6) to 
1:4 diluted (No. 8) serum. 9 - 1 3 ) Anti-PMN-I antiserum 
in the concentration range from concentrated (No. 9) to 
1:16 diluted (No. 13) antiserum. 
its own proteinases112J, but could also be rele­
vant for the protection of tissue in infectious 
diseases because of the inadequate concen­
tration of serum inhibitors* l]. Probably, they 
are also involved in the regulation of tumor 
growth i 4 4 i. However, further investigations have 
to clarify the precise role of PMN-I in physiolo­
gical and pathological events as discussed in the 
accompanying paper. 
We thank U. Stauffer and N. Joswig for their skillful 
technical assistance. We would also like to thank Prof. 
D. K. Hammer, Prof. H. Fritz and Dr. F. Fiedler for 
advice and helpful discussions. 
Literature 
1 Larson, G .L . & Henson, P.M. (1983) Annu. Rev. 
Immunol. 1, 335—359. 
2 Voetman, A . A . , Weening, R.S., Hamers, M . N . , 
Meerhof, L .J . , Bot , A. & Roos, D. ( 1 9 8 1 ) / . Clin. 
Invest. 67, 1541-1549. 
3 Klebanoff, S.J. & Clark, R .A. (1978) The Neutro­
phil; Function and Clinical Disorders, pp. 3 5 - 7 2 , 
North-Holland Publ. Comp., Amsterdam. 
4 Weiss, S.J. & LoBuglio, A . F . (1982) Lab. Invest. 
47, 5 - 1 8 . 
5 Travis, J. & Johnson, D. (1981) Methods Enzymol 
80, 754 -765 . 
6 Barrett, A. J. (198 \ ) Methods Enzymol. 80, 
737_754. 
7 Brzin, J., Kopitar , M. & Turk, V. (1983) Hoppe-
Seyler's Z. Physiol Chem. 364, 1475-1480. 
8 Remold-O'Donnell, E. ( 1 9 8 5 ) / . Exp. Med. 162, 
2142-2155. 
9 Janoff, A. & Blondin, J. (1971) Lab. Invest. 25 , 
. 5 6 5 - 5 7 1 . 
10 Trefz, G. & Geiger, R. (1987) Biol. Chem. Hoppe-
Seyler 368, 1343—1353, succeeding paper. 
11 Davies, P., Rita, G. Α., Krakauer, Κ. & Weissmann, 
G. (1971) Biochem. J. 1 2 3 , 5 5 9 - 5 6 9 . 
12 Dubin, Α., Potempa, J. & Silberring, J. (1985) Int. 
J. Biochem. 17, 509 -513 . 
13 Marossy, K. , Hauck, M. & Elödi , P. (1980) Bio-
chim. Biophys. Acta 615 , 2 3 7 - 2 4 5 . 
14 Valentine, R., Goettlich-Riemann, W., Fisher, G. & 
Rucker, R. B. (1981) Proc. Soc. Exp. Biol Med. 
168, 238 -244 . 
15 Talstad, I . , Dalen, H . & Lehmann, V. {\9%3) Acta 
Pathol Microbiol Scand. Sect. C 91, 4 0 3 - 4 1 1 . 
16 Kabat, E.A. & Mayer, M . M . (1964) Experimental 
Immunochemistry, 2nd edn., pp. 559—563, Charles 
C. Thomas Publ., Springfield, Il l inois, U.S.A. 
17 Laemmli, U . K . (\910)Nature (London) 222, 
680-685 . 
1342 P. Hintz, Μ. Jochum and H. Mossmann Vol. 368 (1987) 
18 Görg, Α., Postel, W. & Westermeier, R. (1978) Anal 
Biochem. 89, 6 0 - 7 0 . 
19 Greenwood, F.C. & Hunter, W.M. (1963) Biochem. 
/ . 89, 114-123. 
20 Towbin, Η , Staehelin, T. & Gordon, J. (1979) 
Proc. Natl Acad. Sei. U.S.A. 76, 4350-4354 . 
21 Batteiger, B., Newhall, W.J. & Jones, R.B. (1982) 
/. Immunol. Methods 55, 297 - 307 . 
22 Hjorth, R., Jonsson, A.-K. & Vretblad, P. (1981) 
/. Immunol. Methods 43 , 9 5 - 1 0 1 . 
23 Pappenheim, A. (1948) in Mikroskopische Technik 
(Romeis, Β. ed.) p. 320, Oldenbourg, München. 
24 Wallach, D . H . & Kamat, V . B . (1966)Methods 
Enzymol 8, 164-172. 
25 Laurent, T.C. & Killander, J. ( 1 9 6 4 ) / . Chrom. 
14, 317 -330 . 
26 Lineweaver, H. & Burk, D. (1934) / . Am. Chem. 
Soc. 56, 658 -666 . 
27 Henderson, P.J. F. (1972) Biochem. J. 1 2 7 , 3 2 1 -
333. 
28 Bieth, J.G. (1980) Bull Europ. Physiopath. Resp. 
16 Suppl., 183-195. 
29 Wenzel, H. R., Engelbrecht, S., Reich, H . , Mondry, 
W. & Tschesche, H. (1980) Hoppe-Seyler's Z. 
Physiol. Chem. 361, 1413-1416. 
30 Castillo, M.J . , Nakajima, K . , Zimmerman, Μ. & 
Powers, J.C. (1979) Anal. Biochem. 99, 5 3 - 6 4 . 
31 Bergmeyer, H. U. , Bergmeyer, J. & Graßl , M. eds. 
(1984) Methods of Enzymatic Analysis, vol. 5, 
pp. 569 -579 , Verlag Chemie, Weinheim/Bergst. 
32 Del Mar, E.G., Largman, C , Brodrick, J.W. & 
Geokas, M.C. (\9T9) Anal Biochem. 9 9 , 3 1 6 - 3 2 0 . 
33 Harper, J.W., Ramirez, G. & Powers, J.C. (1981) 
Anal. Biochem. 1 1 8 , 3 8 2 - 3 8 7 . 
34 Green, G.D.J. & Shaw, E. (1919) Anal Biochem. 
93, 223-226. 
35 Fiedler, F., Seemüller, U. & Fritz, H . (1984) in 
Methods of Enzymatic Analysis (Bergmeyer, H. U . , 
Bergmeyer, J. & Graßl, Μ. eds.) vol. 5, pp. 297-3 14, 
Verlag Chemie, Weinheim/Bergstr. 
36 Ako, H. , Ryan, C A . & Foster, R.J. (1972) Biochem. 
Biophys. Res. Commun. 46, 1639-1645. 
37 Hannibal-Friedrich, O., Chun, M. & Sernetz, M. 
(19SÖ) Biotechnol. Bioengin. 22, 157-175. 
38 Mossmann, H. , Bamberger, U . , Velev, B .A. , Gehrung, 
Μ. & Hammer, D .K. ( 1 9 8 6 ) / . Leuk. Biol. 39, 
153-165. 
39 Ouchterlony, Ö. {195%) Prog. Allergy 5, 1-78. 
40 Marossy, K. , Hauck, M. & Elödi, P. (1981) Biochim. 
Biophys. Acta 662, 3 6 - 4 0 . 
41 Travis, J. & Salvesen, G.S. (1983) Annu. Rev. Bio-
chem. 52, 655-709. 
42 Fritz, H. , Seemüller, U. & Tschesche, H. (1984) in 
Methods of Enzymatic Analysis, (Bergmeyer, H. U. , 
Bergmeyer, J. & Graßl, Μ. eds.) vol. 5, pp. 74 -98 , 
Verlag Chemie, Weinheim/Bergstr. 
43 Beatty, K. , Bieth, J. & Travis, J. ( 1 9 8 0 ) / . Biol 
Chem. 255, 3931-3934. 
44 Giraldi, T., Sava, G., Kopitar, M. , Brzin, J. & Turk, V. 
( 1 9 8 0 ) £ u / \ / . Cancer 16, 449-454 . 
Petra Hintz and Dr. Horst Mossmann*, Max-Planck-Institut für Immunbiologie, 
Stübeweg 5 1 , D-7800 Freiburg. 
Dr. Marianne Jochum, Abteilung für Klinische Chemie und Klinische Biochemie in der Chirurgischen Kl in ik Innen-
stadt der Universi tät München, 
Nußbaums t r aße 20, D-8000 München 2. 
* To whom correspondence should be addressed. 
